Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag
Abstract Background Understanding patients’ perspectives regarding drug tolerability, in addition to effectiveness, provides a complete picture of the patient experience and supports more informed therapeutic decision-making. The item library of the National Cancer Institute’s Patient-Reported Outco...
Main Authors: | Stacy Davis, Teresa Edwards, Lindsey Norcross, Sheri Fehnel, Amélie Beaudet, Marie Eckart, John Fastenau |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2023-12-01
|
Series: | Journal of Patient-Reported Outcomes |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41687-023-00673-w |
Similar Items
-
Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
by: Tian Qi Wang, et al.
Published: (2018-10-01) -
Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
by: Minji K. Lee, et al.
Published: (2020-12-01) -
Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events
by: Shan-Shan Yang, et al.
Published: (2021-07-01) -
Selexipag in pregnancy and pulmonary arterial hypertension
by: Sweta Mohanty, et al.
Published: (2023-01-01) -
Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
by: Mizuki Momoi, et al.
Published: (2022-01-01)